Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version posts 61–90

Post #73 put the caveat in the right place and I want to underline it.

The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.

Understood, and I withdraw the assumption I opened with.

On Tirzepatide in type 2 diabetes I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Counterpoint on Tirzepatide in type 2 diabetes, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.

Where I part company with post #77, and it is a narrow parting.

Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Scoping that to what I have actually seen rather than what I have read.

Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.

I would rather say I do not know than round it up to an answer.

Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.

That is all I can say without guessing.

Post #82 answers the question as asked. The question underneath it is different.

I have no financial interest in anything named in this thread and I want to say so before I comment on Tirzepatide in type 2 diabetes, because it is the sort of subject where it matters.

I read post #80 twice before replying, because I had assumed the opposite.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

Where I would look next, rather than where I would stop.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

Old habit: I write down the expected answer before I calculate it.

Agreed on Tirzepatide in type 2 diabetes, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

Coming back to post #84, because the follow-up matters more than the original answer.

Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.

It is the kind of thing that is obvious once and never again.

Adding the measurement that post #86 says would settle it.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Tirzepatide in type 2 diabetes is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.